ASTHMA/COPD

3. Device that helps with proper administration by ensuring medications go directly to the site of action
6. Mutation of this gene leads to alpha 1 antitrypsin deficiency
7. Montelukast has a boxed warning for these types of events
13. Time course of COPD over years despite treatment
17. Characterized as a peak flow 80-100% of personal best and no symptoms in an asthma action plan
19. Pathophysiology of COPD includes airflow obstruction and ___
23. Formoterol onset of action
24. Rinse and spit after ICS to prevent ___
25. Heterogenous disease, usually characterized by chronic airway inflammation

1. Formoterol is a ___
2. Low dose ICS-formoterol PRN is the ___ reliever
4. ___ medications contain an ICS in asthma
5. Ipratropium is a ___
8. Defined as an acute narrowing of the airways as a result of exercise
9. Questionnaire assessing health status
10. The most reproducible and objective measurement of airflow obstruction
11. Budesonide is an ___
12. Volume of air exhaled forcefully in the first second to maximal expiration
14. Clinical guide to initiate pharmacological treatment by assessing symptoms and exacerbation history
15. ___ medications are provided to all patients for breakthrough symptoms
16. Questionnaire developed to measure breathlessness
18. Take medications ___ prior to exercise for prevention
20. ACOS should be treated as ___
21. Prevalence of COPD is ___ related to the prevalence of tobacco smoking
22. Proposed term to illustrate the complex and dynamic series of interactions over time in COPD